First-line therapy in relapsing remitting multiple sclerosis - 13/06/18
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Today, first-line treatments for multiple sclerosis include injectable immunomodulators – some of which have been on the market for nearly 25 years – as well as teriflunomide and dimethyl fumarate, which are more recent, but have opened the way for oral treatments. These drugs are considered similar in effectiveness, and their safety and side-effect profiles are generally reassuring. These treatments have been associated with a reduction in radiological and clinical disease activity, and a positive effect on patient quality of life, especially when introduced early in the disease process. This article will discuss data on first-line treatments currently available in France, their effectiveness and safety, and their place in pediatric patients and in woman who plan to become pregnant.
Le texte complet de cet article est disponible en PDF.Keywords : Multiple sclerosis, Treatment, Interferon, Glatiramer acetate, Fumarates, Teriflunomide
Plan
Vol 174 - N° 6
P. 419-428 - juin 2018 Retour au numéro
Article précédent
- Atypical inflammatory demyelinating lesions and atypical multiple sclerosis
- X. Ayrignac, C. Carra-Dallière, P. Labauge
- How much progress has there been in the second-line treatment of multiple sclerosis: A 2017 update
- A. Maarouf, C. Boutière, A. Rico, B. Audoin, J. Pelletier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?